AOD-9604 – Comprehensive Research Overview (2026)

AOD-9604 is a synthetic 16-amino-acid peptide fragment derived from the C-terminus of human growth hormone (hGH fragment 177–191). It was designed to retain the lipolytic (fat-burning) properties of hGH while eliminating its growth-promoting and diabetogenic effects. AOD-9604 is primarily researched for targeted fat loss, body composition improvement, and joint/cartilage support. It holds GRAS (Generally Recognized As Safe) status as a food ingredient in the US.

→ View AOD-9604 (for laboratory research use only)

Chemical Structure and Properties

  • Sequence: hGH fragment 177–191 (Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe)
  • Molecular Weight: ≈1,817 Da
  • Form: Lyophilized powder for subcutaneous injection
  • Key Feature: Retains lipolytic activity of hGH without IGF-1 elevation or insulin resistance

Mechanism of Action

  • Mimics the lipolytic region of hGH, stimulating fat breakdown (lipolysis) in adipose tissue.
  • Inhibits lipogenesis (new fat formation) without affecting blood glucose or IGF-1.
  • May interact with β-adrenergic receptors in adipose tissue.
  • Emerging research suggests cartilage and joint repair properties via TGF-β modulation.

Clinical Evidence and Research Findings

Phase 1/2 trials confirmed safety and fat-loss activity. A Phase 3 trial for obesity was conducted but did not meet primary endpoints for regulatory approval. Preclinical data show significant reductions in body fat without the side effects of full hGH. Joint and cartilage research is ongoing, with promising signals in osteoarthritis models.

→ Interested in researching AOD-9604? View Product Options

Benefits (Research & Clinical Observations)

  • Targeted fat loss without IGF-1 elevation
  • No effect on blood glucose or insulin sensitivity
  • Potential joint and cartilage repair benefits
  • GRAS status supports favorable safety profile

Typical Dosing Protocols (Off-Label / Compounded)

  • Common protocols: 300–500 μg subcutaneous once daily (fasted, morning)
  • Cycles: 4–12 weeks
  • Often combined with CJC-1295/Ipamorelin for broader body composition effects

Safety Profile and Side Effects

AOD-9604 has an excellent safety profile with GRAS status. Common side effects: mild injection-site reactions. No significant effects on glucose, IGF-1, or thyroid function reported.

Summary

AOD-9604 is a targeted lipolytic hGH fragment with a strong safety profile and emerging joint repair research. It offers fat-loss benefits without the metabolic risks of full hGH. As with all compounds in this library, AOD-9604 is not an approved drug and should only be considered under qualified medical supervision.

For Laboratory Research Use View AOD-9604 →

Disclaimer This overview is strictly educational and based on publicly available scientific literature as of April 2026. It does not constitute medical advice. Always consult a qualified healthcare professional and comply with all applicable laws and regulations.